In September 2026, the European Commission adopted a proposal for a Council recommendation on evidence-based, targeted cardiovascular health checks. The proposal sits within the Safe Hearts Plan announced in December 2025. Member States would adapt any approach to their own health systems. It is not a binding screening programme, an employer mandate or proof that screening reduces clinical events. The distinction matters for multinational employers comparing public provision and insured benefits across countries. A plan that pays for tests may offer convenience, but its actual value depends on who is reached, what happens after an abnormal result and whether employees can obtain appropriate follow-up care.
The Commission cites cardiovascular disease as a major cause of death, disability, early retirement and absenteeism in Europe. Those burdens provide a reason to examine prevention carefully; they do not establish a return on any particular corporate health benefit. The Council must still consider the proposal, and any national measures would have their own design and timetable.
Where workplace cover can help
An employer may already fund risk assessments, check-ups or digital coaching. Benefits teams should map those services against the local public pathway before buying more screening capacity. The map should specify eligibility, age and risk criteria, provider quality, referral routes, waiting times, employee charges and support for people working remotely or across borders. A test with no accessible follow-up is a weak benefit, however attractive its enrolment figures.
Targeting also raises equity questions. Employees in lower-paid, shift or mobile roles may face greater practical barriers to attendance than office staff. A programme should measure participation by relevant group without exposing individual health information to an employer. Appropriate clinical governance, confidentiality and voluntary participation must be established locally. Employers should avoid claiming that risk scores diagnose disease or that an app can replace a clinician.
Evidence for boards and insurers
The board can request a small set of measures: eligible population, take-up, completed referrals, clinically appropriate follow-up, satisfaction and any observed differences between groups. Longer-term health outcomes need a credible comparator and adequate time; raw screening counts cannot demonstrate avoided events. Insurers and brokers should separate service costs from claims experience and explain whether the evidence is strong enough to support pricing changes.
For a multinational, the useful exercise is a country-by-country inventory. Public access, data protection, medical practice and insurer networks differ. A central benefits policy can set evaluation standards while local teams determine what can be offered lawfully and usefully.
Share this:
- More [2]
